These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 16231594

  • 21. [Steatosis and steatohepatitis in diabetic patient].
    Hůlek P, Dresslerová I.
    Vnitr Lek; 2011 Apr; 57(4):364-7. PubMed ID: 21612059
    [Abstract] [Full Text] [Related]

  • 22. The clinical aspects of non-alcoholic fatty liver disease.
    Björnsson E.
    Minerva Gastroenterol Dietol; 2008 Mar; 54(1):7-18. PubMed ID: 18299664
    [Abstract] [Full Text] [Related]

  • 23. Nonalcoholic fatty liver disease.
    Angulo P.
    Rev Gastroenterol Mex; 2005 Nov; 70 Suppl 3():52-6. PubMed ID: 17471859
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Nonalcoholic fatty liver disease and lipids.
    Wierzbicki AS, Oben J.
    Curr Opin Lipidol; 2012 Aug; 23(4):345-52. PubMed ID: 22617751
    [Abstract] [Full Text] [Related]

  • 28. Fatty liver disease in children.
    Marion AW, Baker AJ, Dhawan A.
    Arch Dis Child; 2004 Jul; 89(7):648-52. PubMed ID: 15210498
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Weight loss as a treatment for nonalcoholic fatty liver disease.
    Clark JM.
    J Clin Gastroenterol; 2006 Mar; 40 Suppl 1():S39-43. PubMed ID: 16540766
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Pediatric nonalcoholic fatty liver disease.
    Lerret SM, Skelton JA.
    Gastroenterol Nurs; 2008 Mar; 31(2):115-9. PubMed ID: 18391799
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C.
    Rafiq N, Younossi ZM.
    Expert Rev Gastroenterol Hepatol; 2008 Apr; 2(2):207-15. PubMed ID: 19072356
    [Abstract] [Full Text] [Related]

  • 35. Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH).
    Yamagishi S, Nakamura K, Inoue H.
    Med Hypotheses; 2005 Apr; 65(2):377-9. PubMed ID: 15922116
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Evolving trends in nonalcoholic fatty liver disease.
    Delgado JS.
    Eur J Intern Med; 2008 Mar; 19(2):75-82. PubMed ID: 18249301
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Treatment strategies in nonalcoholic fatty liver disease.
    Tilg H, Kaser A.
    Nat Clin Pract Gastroenterol Hepatol; 2005 Mar; 2(3):148-55. PubMed ID: 16265156
    [Abstract] [Full Text] [Related]

  • 40. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial.
    Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA.
    Hepatology; 2009 Jan; 49(1):80-6. PubMed ID: 19053049
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.